Accelovance

Accelovance acquires THERAMetrics’ CRO services

Wednesday, June 8, 2016

Accelovance, a global CRO focusing in vaccines, oncology, and general medicine, has announced further expansion of European CRO services with the acquisition of THERAMetrics Holding‘s three CRO subsidiaries and phase I unit in Germany, Italy and Romania. In addition to the employees and facilities associated with these European subsidiaries, Accelovance will also assume management of THERAMetrics’ ongoing clinical program work in the U.S.

[Read More]

Accelovance, FHI 360 ink agreement

Thursday, November 5, 2015

Accelovance, a Rockville, Md.-based global CRO focusing in oncology, vaccines, and general medicine, and FHI 360, a Durham, N.C.-based global nonprofit organization with CRO capabilities focusing on clinical research in developing countries, have entered into a strategic alliance to more comprehensively serve the international drug development research efforts of pharmaceutical, governmental and nonprofit organizations.

[Read More]

Midwest Melanoma, Accelovance partner

Friday, September 18, 2015

Accelovance, a Rockville, Md.-based global CRO focusing in oncology, vaccines and general medicine, and the Midwest Melanoma Partnership (MMP), a nonprofit organization dedicated to improving therapies for patients diagnosed with malignant melanoma, have entered into a strategic alliance to enhance the research and advancement of treatment options for patients suffering from melanoma.

[Read More]

Accelovance to expand in Wales

Thursday, August 13, 2015

Accelovance, a Rockville, Md.-based CRO focused on oncology, vaccines and general medicine, is expanding its international presence with a new facility in Wales, which is expected to create 70 new clinical research jobs. The expansion will be financed by the Welsh government, enabling Accelovance to grow its global workforce over the next two years.

[Read More]

Panacea Pharmaceuticals engages Accelovance for clinical development

Wednesday, February 11, 2015

Panacea Pharmaceuticals, based in Gaithersburg, Md., and Accelovance, a CRO headquartered in Rockville, Md., have established a clinical development services agreement to develop and advance Panacea’s oncology immunotherapy pipeline. Accelovance will support Panacea’s clinical development strategies by offering scientific/medical and regulatory experience, in addition to providing CRO support through project management, clinical monitoring, data management, biostatistics and safety services for Panacea’s clinical trials.

[Read More]

Accelovance joins iMedNet Partner Program

Friday, September 27, 2013

Accelovance, a CRO focused in early phase oncology, vaccines and general medicine development, has joined the iMedNet Partner Program, established by MedNet, a global life sciences technology company specializing in clinical study management systems. Accelovance now can offer iMedNet EDC to clients as an advanced solution for the data management needs associated with clinical trial programs while providing significant cost savings compared with similar platforms.

[Read More]